HDP-101, a novel antibody-drug conjugate, targets BCMA with a synthetic amanitin payload that causes tumor cell death.

Lifordi Immunotherapeutics, Inc., a biotech company developing antibody-drug conjugates (ADCs) for the treatment of ...

Antibody-drug conjugates (ADCs) represent a significant advancement in cancer treatment, particularly within China's burgeoning oncology sector.

Recent Studyt By Kuick highlights more than 600 Cancer Antibody Drug conjugates in Clinical TrialsDelhi, Sept. 19, 2024 ...

It represents 82% of the ADC pipeline in major APAC markets. A surge in antibody-drug conjugates (ADCs) is driving China to ...

Another breakthrough has been with ADCs in combination with other treatments, such as an immunotherapy that inhibits the ...

No writing assistance was utilized in the production of this manuscript. Several antibody–drug conjugates (ADCs), using different combinations of antibody, cytotoxic agents and linkers ...

A drug that delivers chemotherapy directly to tumors has shown impressive activity against some of the hardest-to-reach ...

Bispecific antibody drug conjugates (BsADCs) are emerging as a transformative class of cancer therapeutics, combining the specificity of bispecific antibodies with the potent cytotoxicity of drug ...

Presentations to highlight progress in development of IND candidates ZW220 and ZW251 based on Zymeworks’ proprietary antibody ...

In the chemical world, the tiny hyphen in antibody-drug conjugates—or ADCs, as they’re commonly known—does a lot more work than the perfunctory punctuation suggests. That hyphen stands for ...